The FDA first approved Victoza in 2010 for Type 2 diabetes, later expanding its use in 2019 as a pediatric, injectable treatment for patients 10 or older. Hikma’s generic includes similar warnings to the brand-name drug, such as risks of thyroid C-cell tumors, pancreatitis, hypoglycemia, kidney failure and acute gallbladder disease.
The injectable GLP-1 is indicated to improve glycemic control in patients 10 and older. This marks the second GLP-1 medicine with a generic option. In November, the FDA approved a generic for Byetta (exenatide), another diabetes therapy.
A few other drugmakers are preparing to enter the GLP-1 market, which remains dominated by Eli Lilly and Novo Nordisk. In June, Teva Pharmaceuticals launched its generic version of Victoza. Sandoz plans to release a generic for Ozempic (semaglutide) when the market opens in 2030.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
